These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19856097)

  • 21. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
    Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
    BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
    J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
    Kleibl Z; Kristensen VN
    Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy in the treatment of hereditary breast cancer.
    Pierce LJ; Haffty BG
    Semin Radiat Oncol; 2011 Jan; 21(1):43-50. PubMed ID: 21134653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
    Yang X; Wu J; Lu J; Liu G; Di G; Chen C; Hou Y; Sun M; Yang W; Xu X; Zhao Y; Hu X; Li D; Cao Z; Zhou X; Huang X; Liu Z; Chen H; Gu Y; Chi Y; Yan X; Han Q; Shen Z; Shao Z; Hu Z
    PLoS One; 2015; 10(4):e0125571. PubMed ID: 25927356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
    Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
    Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.
    Wang K; Ye Y; Xu Z; Zhang X; Hou Z; Cui Y; Song Y
    Cancer Genet Cytogenet; 2010 Jul; 200(1):40-6. PubMed ID: 20513533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer.
    Ouhtit A; Gupta I; Shaikh Z
    Front Biosci (Elite Ed); 2016 Jan; 8(2):289-98. PubMed ID: 26709662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
    Reid S; Schindler D; Hanenberg H; Barker K; Hanks S; Kalb R; Neveling K; Kelly P; Seal S; Freund M; Wurm M; Batish SD; Lach FP; Yetgin S; Neitzel H; Ariffin H; Tischkowitz M; Mathew CG; Auerbach AD; Rahman N
    Nat Genet; 2007 Feb; 39(2):162-4. PubMed ID: 17200671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and future role of genetic screening in gynecologic malignancies.
    Ring KL; Garcia C; Thomas MH; Modesitt SC
    Am J Obstet Gynecol; 2017 Nov; 217(5):512-521. PubMed ID: 28411145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
    Baynes C; Healey CS; Pooley KA; Scollen S; Luben RN; Thompson DJ; Pharoah PD; Easton DF; Ponder BA; Dunning AM;
    Breast Cancer Res; 2007; 9(2):R27. PubMed ID: 17428325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.